SCHEMBL269636

SCHEMBL269636

Nc1nc(N)c2ccccc2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCPS Q96C86 1/20 1.00
DHFR P00374 2/20 0.63
ALDH1A1 P00352 3/20 0.63
HPGD P15428 3/20 0.63
HSD17B10 Q99714 3/20 0.63
NUDT1 P36639 2/20 0.63
CYP1A2 P05177 1/20 0.63
ADORA2A P29274 6/20 0.61
SMN1; SMN2 Q16637 3/20 0.56
KDM4E B2RXH2 2/20 0.56
GLA P06280 2/20 0.56
CASP1 P29466 2/20 0.56
CASP7 P55210 2/20 0.56
CHRM2 P08172 1/20 0.56
ADRA2A P08913 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
CHRM1 P11229 1/20 0.56
NQO2 P16083 1/20 0.56
MAOA P21397 1/20 0.56
DRD1 P21728 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29375878 1.00 DCPS (1.00) DCPSDHFRALDH1A1HPGDHSD17B10
SCHEMBL30468763 0.98 DCPS (0.95) DCPSDHFRALDH1A1HPGDHSD17B10
Hydrochloric Acid SCHEMBL27786605 0.98 DCPS (0.95) DCPSDHFRALDH1A1HPGDHSD17B10
Hydrochloric Acid SCHEMBL6601650 0.98 DCPS (0.95) DCPSDHFRALDH1A1HPGDHSD17B10
Hydrazine SCHEMBL29011033 0.96 DCPS (0.91) DCPSDHFRALDH1A1HPGDHSD17B10
Hydrazine SCHEMBL29011024 0.85 DCPS (0.72) DCPSDHFRALDH1A1HPGDHSD17B10
Pyrrole SCHEMBL5652472 0.81 DCPS (0.66) DCPSDHFRALDH1A1HPGDHSD17B10
SCHEMBL9605513 0.78 DHFR (1.00) DCPSDHFRNUDT1ADORA2A
SCHEMBL72801 0.78 DCPS (0.64) DCPSALDH1A1HPGDHSD17B10NUDT1
SCHEMBL29583288 0.78 DCPS (0.64) DCPSALDH1A1HPGDHSD17B10NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 976 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570956-B2 Efficient derivation of stable pluripotent bovine embryonic stem cells THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-03-10 US claimed
US-20250092358-A1 In Vitro Breeding Systems and Methods in Livestock ABS GLOBAL, INC. (US) 2025-03-20 US claimed
US-20250075175-A1 EFFICIENT DERIVATION OF STABLE PLURIPOTENT BOVINE EMBRYONIC STEM CELLS UNIV CALIFORNIA (US) 2025-03-06 US claimed
US-20240409892-A1 METHOD OF DIRECTED DIFFERENTIATION PRODUCING CORNEAL ENDOTHELIAL CELLS, COMPOSITIONS THEREOF, AND USES THEREOF ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) 2024-12-12 US claimed
US-20240342161-A1 BISBENZYLISOQUINOLINES AS CONDITIONING AGENTS FOR IMMUNE THERAPY Escend Pharmaceuticals, Inc. 2024-10-17 US claimed
EP-4416268-A1 METHODS FOR PRODUCING CARTILAGE AND BONES Murdoch Children's Research Institute (AU) 2024-08-21 EP claimed
US-12065671-B2 Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-08-20 US claimed
CN-118355110-A Method for producing cartilage and bone 默多克儿童研究所 2024-07-16 CN claimed
CN-118142359-A Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof 万华化学集团股份有限公司 2024-06-07 CN claimed
EP-4346395-A1 IN VITRO BREEDING SYSTEMS AND METHODS IN LIVESTOCK ABS Global, Inc. (US) 2024-04-10 EP claimed
US-5874438-A A DRUG TREATING BRAIN DISORDERS, DISEASES OF CENTRAL NERVOUS SYSTEM, DEMENTIA, DEPRESSION, MYOTONIC DYSTROPHY, ASTHMA BAYER AKTIENGESELLSCHAFT (DE) 1999-02-23 US claimed
US-5760230-A TREATING DISEASES OF CENTRAL NERVOUS SYSTEM BAYER AKTIENGESELLSCHAFT (DE) 1998-06-02 US claimed
US-5686459-A ANTICOAGULANTS HOFFMANN-LA ROCHE INC. (US) 1997-11-11 US claimed
CN-1136567-A Dioxide pyrrolo-pyrrolo derivatives HOFFMANN LA ROCHE (CH) 1996-11-27 CN claimed
EP-0728758-A1 Dioxopyrrolo-pyrrole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1996-08-28 EP claimed
US-5534518-A Insecticidal substituted-2,4-diaminoquinazolines FMC CORPORATION (US) 1996-07-09 US claimed
EP-0684824-A4 INSECTICIDAL SUBSTITUTED-2,4-DIAMINOQUINAZOLINES. FMC CORP (US) 1996-02-14 EP claimed
EP-0684824-A1 INSECTICIDAL SUBSTITUTED-2,4-DIAMINOQUINAZOLINES FMC CORPORATION (US) 1995-12-06 EP claimed
WO-1994018980-A1 INSECTICIDAL SUBSTITUTED-2,4-DIAMINOQUINAZOLINES FMC CORPORATION (US) 1994-09-01 WO claimed
EP-0253396-A2 Process for preparing 5,6-substituted-2,4-quinazolinediamines and intermediates WARNER-LAMBERT COMPANY (US) 1988-01-20 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240342161-A1 BISBENZYLISOQUINOLINES AS CONDITIONING AGENTS FOR IMMUNE THERAPY NFATC1, CTNNB1, CAMK1D DCPS 4331/4885DHFR 3196/4885ALDH1A1 2907/4885
US-12570956-B2 Efficient derivation of stable pluripotent bovine embryonic stem cells WNT1, PHKA1, ACVR1 DCPS 4248/4885DHFR 3987/4885ALDH1A1 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.